FDA
- Status: approved
🇺🇸 Bivalent OPV 4 week interval in United States
Bivalent OPV 4 week interval (Bivalent OPV 4 week interval) regulatory status in United States.
Marketing authorisation
Bivalent OPV 4 week interval in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Bivalent OPV 4 week interval approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Bivalent OPV 4 week interval in United States?
International Centre for Diarrhoeal Disease Research, Bangladesh is the originator. The local marketing authorisation holder may differ — check the official source linked above.